Abstract : Adrenocortical hormones are effective in many, but not all, cases of autoimmune pancreatitis AIP . While effective treatment for refractory and recurrent cases of AIP has not been established, immunomodulators are sometimes used. We examined the therapeutic effect of the immunomodulator FK506 against AIP using an animal model : aly / aly male mice. Mice were divided into three groups based on FK506 dose : 1 mg / kg, 2 mg / kg, and non-administration pancreatitis groups. Pancreatic exocrine gland injury was regarded as pancreatitis and pancreatic endocrine injury was regarded as insulitis. Histological evaluation of pancreatic tissue at 16 and 24 weeks of age was performed quantitatively using ImageJ software, and the three groups were compared. The pancreatitis group developed pancreatitis at 24 weeks of age, but onset of pancreatitis was suppressed in the 1 mg group. However, pancreatitis development was not suppressed in the 2 mg group, and pancreatitis developed from as early as 16 weeks of age. In the pancreatitis group, insulitis resulted in morphological changes such as shrinkage of pancreatic islets of Langerhans as in ammatory cell in ltration into pancreatic acinar cells became stronger. No signi cant difference was observed between the 1 mg group and the pancreatitis group in the islet area but, in the 2 mg group, there was significant reduction in area compared to the pancreatitis group and the 1 mg group. Although administration of FK506 at a low dose had an effect of suppressing the onset of pancreatitis, administration at a higher dose appeared to exacerbate pancreatitis.
pancreatitis AIP as a disease has been proposed, and the pathophysiology of AIP is gradually being elucidated. AIP is pancreatitis with hypergammaglobulinemia, high levels of hyper-IgG / IgG4 or other ndings that suggest involvement of autoimmune mechanisms.
In many cases of AIP, adrenocortical hormone therapy is effective, but refractory and recurrent AIP cases are also common. Although immunomodulatory drugs are considered to be effective for refractory and recurrent cases, and are administered occasionally, their ef cacy has not yet been assessed.
We have conducted and reported histological and immunological studies of pancreatic and extra-pancreatic lesion in autoimmune pancreatitis AIP using aly mice as an animal model of autoimmune pancreatitis. Pancreatic lesions were analyzed as exocrine disorder and endocrine disorder, and histologically analyzed as pancreatitis and insulitis, respectively. In aly mice, ndings of pancreatitis emerged from 16 weeks of age, and insulitis occurred somewhat later from 24 weeks of age and more weight loss was observed as pancreatitis became more severe.
In this article, we describe histological and immunological studies of pancreatic and extrapancreatic lesions in AIP, using aly mice as an AIP model, and our evaluation of the effects of two doses of the immunomodulatory drug FK506 common name : tacrolimus on these lesions.
To evaluate the therapeutic effect of FK506, pancreatic lesions were analyzed as exocrine disorder and endocrine disorder, and histologically analyzed as pancreatitis and insulitis, respectively. In addition, changes in pancreatic exocrine secretory cells, CD8-positive T cells, CD4-positive T cells, CD11b-positive cells, Foxp3 and IFN-R were histologically assessed.
Methods

Housing and treatment of mice, and autopsy procedure
Eight-week-old aly / aly male mice were allocated to three groups : two administration treatment groups and one non-administration pancreatitis group. Each group consisted of 12 mice. The mice had been raised in a 12-hour light / dark cycle at room temperature 23 , with freely available high-pressure steam sterilized diet and chlorinated drinking water that had been boiled.
The mice in the treatment groups were intraperitoneally administered 1 mg / kg or 2 mg / kg of FK506 Abcam, Cambridge, UK every 2 days with a 27G needle. The mice in the pancreatitis group were intraperitoneally administered 100 mM dimethylsulfoxide DMSO diluted with distilled water in the same manner as treatment group. The volume of DMSO administration was 0.6 ml, based on an estimated body weight of 35 g.
At 16 and 24 weeks of age, blood was collected from the heart of each mouse. Once exsanguination was completed and cardiac arrest was con rmed, samples of pancreatic, splenic and submaxillary gland tissue were collected. Mice were carefully observed during and after this procedure to minimize their pain and determine an appropriate time for euthanasia. Euthanasia was conducted with NO 2 or pentobarbital overdose dose : 50 mg / kg ; working concentration : 64.8 mg / ml ; 27G needle . Organ excision was performed after con rmation of death. For ethical reasons, we performed painful procedures in as short a period as possible. We observed the condition of the mice at least once a week and tried to perform dissection at the time when weight loss more than 20 from the start of the experiment , worsened coat condition and abnormal behavior such as abnormal walking were seen. Autopsy was conducted after blood collection and blood removal by the axillary artery or ventricular puncture, which was performed under anesthesia induced by intraperitoneal administration of pentobarbital to minimize pain.
Preparation of FK506 tacrolimus hydrate solution
Based on an estimated mouse body weight of 35 g and an FK506 dose of 2 mg / kg, a solution of 0.07 mg / ml FK506 was prepared by dissolving 2 mg of FK506 in 50 µl of DMSO and diluting this with 57 ml of physiological saline. However, precipitation of FK506 was observed, and FK506 did not dissolve even when further dilution in DMSO was performed. FK506 was found to be soluble in distilled water. We sought the highest concentration without observing any precipitation, found that 0.07 mg per 0.6 ml was the upper limit, and made the solution with that concentration. We dissolved 10 mg of FK506 in 122 µl of 100 mM DMSO and diluted it with 85.7 ml of distilled water to prepare a 0.14 mg / ml solution for 2 mg / kg dosing 2 mg group . The solution was further diluted to 0.07 mg / ml solution for 1 mg / kg dosing 1 mg group .
Characteristics of the aly mouse
The aly alymphoplasia mouse is a model of immunode ciency in which lymph nodes and Peyer plates are congenitally lost throughout the whole body, and in-vivo lymphocyte function is lacking despite the presence of T cells and B cells. These abnormalities are caused by an autosomal recessive mutation on a single gene. Histologically, lymphocyte-mediated in ammatory cell in ltration occurs in the pancreas, and pancreatic acinar cell disorder is observed. It is presumed that autoimmune abnormality is involved, so we used the aly mouse as a model of spontaneous pancreatitis. In this study, we used homozygous aly / aly male mice CLEA Japan, Tokyo, Japan as a model of AIP. Various immunode ciencies occur in homozygous aly / aly mice, whereas heterozygous aly mice aly / do not have an immunode ciency. In our study, ndings of pancreatitis in the aly mice emerged from 16 weeks of age, and insulitis occurred from 24 weeks of age.
Hematoxylin-eosin staining
At 16 and 24 weeks of age, we conducted autopsy in four mice from each of the three groups. Pancreatic tissue was fixed in formalin, and this was followed by hematoxylin-eosin HE staining. The excised pancreas was xed with 10 formaldehyde, embedded in paraf n, sectioned, and stained with HE. Images were taken at random in four elds of view, around vessels and ducts of pancreatic tissue in which there was strong infiltration by inflammatory cells. To avoid bias, the numbers of in ammatory cells were counted using open-source software ImageJ, National Institutes of Health, Bethesda, USA . Objectively quanti ed data were analyzed and statistically examined as an index of in ammation. Insulin staining was conducted to quantify the area of the pancreas head and evaluate endocrine cell function. This was done using 24-week-old mice. In each group, relatively large pancreatic islets stained for insulin were randomly photographed for each slide. Ten pancreatic islets were chosen for each slide. The area of the pancreatic islets was measured using ImageJ, and the area size pixel count was used as an index of endocrine function.
Statistical analysis
Statistical analysis was conducted using JMP Pro 13.0.0 SAS, Institute, Cary, NC, USA . Results for the three groups were compared by using the Kruskal-Wallis test to examine differences between groups. For the signi cant differences between groups, a multiple comparison test was conducted using the Steel-Dwass test. P 0.05 was considered statistically signi cant.
Results
Body weight changes
Body weight of the aly mice increased in each group on a weekly basis up to 24 weeks of age, but was suppressed in the drug administration groups. The weight gain in the pancreatitis group was signi cantly higher than in the 1 mg and 2 mg groups P 0.0054 and P 0.0027, respectively , but there was no signi cant difference in body weight gain between the 1 mg and 2 mg groups P 0.1565 . In each group, there was no signi cant change in body weight gain from 18 to 24 weeks of age Fig. 1 .
Evaluation of in ammatory cell in ltration using HE staining
In the pancreatitis group, strong in ammatory cell in ltration was observed around the pancreatic duct from 24 weeks of age. In ammatory cell in ltration was observed from 16 weeks of age in the 2 mg group. In the 1 mg group, in ammation was suppressed at both 16 and 24 weeks of age. According to quanti cation of the in ammatory cells using ImageJ, the number of in ammatory cells at the age of 16 weeks was signi cantly lower in the 1 mg group compared with the 2 mg group P 0.0004 , and signi cantly lower in the pancreatitis group compared with the 2 mg group P 0.001 , but there was no signi cant difference between the 1 mg group and the pancreatitis group P 0.8849 . At 24 weeks of age, inflammation was significantly lower in the 1 mg group compared with the pancreatitis group P 0.001 and compared with the 2 mg group P 0.016 . The difference between the pancreatitis group and the 2 mg group was not significant P 0.818 . On histopathological evaluation, pancreatitis suppression was apparent in the 1 mg group. However, inhibitory effects were not obtained in the 2 mg group, Therapeutic Effect of FK506, Tacrolimus Hydrate on AIP At 16 weeks of age, the inflammatory cell infiltration around the duct in the 2 mg group was significantly stronger compared with that in the pancreatitis and 1 mg group. There was no significant difference between the pancreatitis group and 1 mg group. Compared with the pancreatitis group and 2 mg group at 24 weeks of age, inflammatory cell infiltration was suppressed significantly in the 1 mg group. There was no significant difference in inflammatory cell infiltration between the pancreatitis group and the 2 mg group. and in ammatory cell in ltration was observed from 16 weeks, which was earlier than in the pancreatitis group Figs. 2-4 .
Immunostaining
Insulin Islet cells were stained using insulin staining, and the morphology of islets and in ltrating in ammatory cells were compared. In ammatory cell in ltration was observed in pancreatic islets of Langerhans in areas where in ammatory cell in ltration was strong, and morphological changes such as size reduction and spherical shape collapse were observed in islets of Langerhans.
In areas with less in ammatory cell in ltration, the shape of pancreatic islets of Langerhans was maintained. In the pancreatitis group and the 2 mg group, in which pancreatitic in ammation was strong, islet shrinkage and morphological changes were frequently observed. However, in the 1 mg group, the shape of pancreatic islets was maintained as compared with the other groups Fig. 5 stained. The morphology of cells was maintained in pancreatic islets of Langerhans which showed insulitis was occurring. As with insulin staining, the shape of the pancreatic islet was maintained in the 1 mg group compared with the pancreatitis group and 2 mg group with strong in ammatory cell in ltration Fig. 6 . CD4 and CD8 With CD4 and CD8 staining, cell in ltration of CD4-and CD8-positive T lymphocytes was observed at the sites where in ammatory cell in ltration was observed, and CD4-positive T lymphocyte in ltration was predominant. With HE staining, CD4-and CD8-positive T lymphocyte in ltration was stronger in areas where in ammatory cell in ltration was stronger Fig. 7 .
IFN-R IFN-R -positive cell in ltration was observed in the in ammatory cells surrounding the duct, and strong in ltration of IFN-R positive cells was observed as strong in ammatory cell in ltration was observed, as seen with CD4 and CD8 staining Fig. 8 . CD11b With CD11b staining, CD11b-positive cell in ltration was observed around pancreatic ducts in a diffuse manner in areas where in ammatory cell in ltration was strong. In the 1 mg group, in which in ammatory cell in ltration was suppressed, the numbers of CD11b-positive cells were small. In the 2 mg and pancreatitis groups, CD11b-positive cell in ltration was stronger than in the 1 mg group. There was no signi cant difference in CD11b-positive cell in ltration between the 2 mg group and the pancreatitis group Fig. 9 . Foxp3 Similar to CD11b staining, in ltration of Foxp3-positive cells was diffuse around the pancreatic ducts where in ammatory cell in ltration was strong. Foxp3-positive cell in ltration was observed in the 2 mg group and pancreatitis group with strong in ammatory cell in ltration, but Foxp3-positive cell in ltration was suppressed in the 1 mg group Fig. 10 . 4 Evaluation of endocrine function Evaluation of islet areas by insulin staining showed islet shrinkage and morphological changes in pancreatic islets in which in ammatory cell in ltration was observed. In contrast to the 1 mg group, islet shrinkage and morphological changes were observed in the 2 mg and pancreatitis groups with strong in ammatory cell in ltration, whereas islet size was relatively maintained in pancreatic islets with less in ammatory cell in ltration. Comparison of islet area revealed that the average islet area of the 2 mg group was signi cantly smaller than that of the 1 mg group P 0.0051 and the pancreatitis group P 0.0486 . There was no significant difference in average islet area between the pancreatitis group and the 1 mg group P 0.4123 Fig. 12 .
Discussion
Autoimmune pancreatitis is classi ed as an IgG4-related disease. Histologically, it is characterized by remarkable lymphocyte and plasma cell in ltration, IgG4-positive plasma cell in ltration, storiform brosis and tumor formation. Although adrenocortical hormone is generally effective for treatment of this disease, there are refractory cases and cases in which the therapeutic effect of adrenocortical hormone is poor. In addition, adverse effects due to long-term administration of adrenocortical hormone are problematic, even in cases where therapeutic effects are obtained. There are no de nitive views on treatment for relapsed and refractory cases, but immunomodulators can be administered because they are considered to be effective. FK506 binds to FKBP FK506 binding protein in helper T cells, inhibits calcineurin, and suppresses the action of T cell activation factor. As a result, it inhibits the synthesis and secretion of various cytokines Average islet area in each group. The pancreatic islet area in the 2 mg group was significantly smaller than that in the pancreatitis group and in the 1 mg group. There was no significant difference between the pancreatitis group and the 1 mg group.
such as interleukins typically IL-2 and leads to immunosuppression. In clinical practice, it is used for suppression of rejection during organ transplantation, intractable ulcerative colitis, rheumatoid arthritis, polymyositis, and interstitial pneumonia combined with dermatomyositis, and has a strong immunomodulatory effect. According to the 3rd nationwide AIP survey conducted in Japan, 5,745 patients had AIP in 2011, and more than 80 were treated with adrenocortical hormone 1 . Furthermore, 761 of 925 patients with AIP received steroid therapy 1 . Among them, immunomodulatory drugs were used in 10 cases : azathioprine in four cases, cyclosporine in one case, methotrexate in one case, cyclophosphamide in one case, in iximab in one case, tacrolimus in one case, and the immunomodulatory drug was not speci ed in one case 1 . In Europe and the United States, various immunomodulators have been examined, and case reports describing the use of azathioprine, mizoribine, methotrexate, cyclophosphamide and cyclosporin A have been published. However, it is still unclear which immunomodulatory agents are effective [2] [3] [4] [5] [6] [7] [8] . In fact, rituximab is the most frequently administered in Europe and the United States, and there are reports showing ef cacy in cases that do not respond to adrenocortical hormone. However, rituximab is not covered by insurance in Japan 6 .
According to Ito et al, intravenous administration of FK506 and intraperitoneal administration of caerulein in rats with induced pancreatitis led to dose-dependent exacerbation of pancreatitis 12 .
In addition, it has been reported that administration of FK506 after organ transplantation has resulted in the development of pancreatitis 13 . On the other hand, a study by Hashimoto et al, in which FK506 was subcutaneously administered to aly mice, showed an inhibitory effect on Bcl-2 protein, and a suppressing effect on the onset of pancreatitis due to T cell suppression 14 .
In our study, we investigated inhibitory or inducing effects of FK506 with 1 mg / kg or 2 mg / kg dosing on the onset of pancreatitis. In the 1 mg group, the onset of pancreatitis was suppressed, and in ammatory cell in ltration remained mild compared to the pancreatitis group. However, in the 2 mg group, in ammatory cell in ltration was observed from 16 weeks of age, which was earlier than in the pancreatitis group ; in addition, the onset of pancreatitis could not be suppressed in the 2 mg group, and the pancreatitis worsened. The mechanism of FK506 inducing toxicity and pancreatitis in the mouse and human pancreas has not been clari ed. Although FK506 has a pancreatitis-suppressing effect at some doses, doses higher than the optimal dose may induce pancreatitis via pancreatic stimulation. Various studies of AIP have been conducted using the aly mouse as a model. In our study, weight gain was signi cantly lower in the 2 mg treatment group than in the pancreatitis group. In a previous study, more weight loss was observed as pancreatitis became more severe. However, in our study, while the body weight of each group was increased, the body weight in the pancreatitis group in which pancreatitis developed increased more than in the 1 mg group in which pancreatitis was suppressed . Tayama et al reported that FK506 administration induced hyperglycemia due to abnormality of glucose tolerance and that, as a consequence, the feeding center is suppressed, food intake decreases and body weight decreases 9 . It has also been suggested that other factors such as gastrointestinal disturbance and decreased absorption of food due to a decrease in intestinal ATP are involved 10 11 . Since we used a mouse model of pancreatitis in our study, we did not compare with animals that did not develop pancreatitis. However, we infer that the pharmacological effect of FK506 may have inhibited an increase in body weight. In addition, food intake was not measured in this study, so further investigation is necessary to examine the lower body weight gain in the 2 mg group. Immunohistochemical staining revealed that CD4-positive cells in the 2 mg and pancreatitis groups dominated T lymphocyte cell in ltration. Hashimoto et al subcutaneously administered 2 mg / kg of FK506 to pancreatitis model mice 14 . In our study, although we used the same dose of FK506, we administered it intraperitoneally to optimize accuracy of dosing. In general, blood concentrations of an administered drug are higher following intraperitoneal administration compared with subcutaneous administration. Therefore, we infer that the blood concentration of FK506 was higher in our study than the previous study that used subcutaneous administration. FK506 overdose in humans has been reported to cause renal dysfunction or metabolic disorder, and it has been suggested that FK506 may induce pancreatitis in a dose-dependent manner 15 . In clinical practice, immunomodulators are often administered in combination with steroids.
According to international consensus on the treatment of AIP, administration of immunomodulators without steroids is less effective and should only be used when steroids or rituximab cannot be used. However, it is thought that a certain degree of suppression of in ammation can be obtained even with low-dose FK506 alone 16 . As our study only assessed short-term use of FK506, further research on long-term use is needed. Insulitis was analyzed to evaluate endocrine disorder, but pancreatic islets of Langerhans were found to have shrunk in the areas where there was strong in ammatory cell in ltration into the surrounding pancreatic acinar cells. The morphology of pancreatic islets of Langerhans was maintained in places where inflammatory cell infiltration was weak. As inflammation became stronger, in ltration of in ammatory cells into acinar cells as well as endocrine cells was observed. In ammatory cell in ltration was suppressed in the 1 mg group but, in the comparison of the pancreatic islet area, there was no signi cant difference from the pancreatitis group. From a histological standpoint, the suppression effect of FK506 on endocrine ability was not observed.
In a previous study, we observed inflammatory cell infiltration and vacuolation around the interlobular pancreatic duct in the AIP group from 16 weeks of age, pancreatic acinar cell loss from 24 weeks of age, and pancreatic acinar cell loss became prominent after 28 weeks of age. In addition to in ammatory cell in ltration, brosis has been observed 17 . Our study collected data up to 24 weeks of age, and it is possible that endocrine function differences might have appeared in the pancreatitis and 1 mg groups with longer-term use of FK506. Thus, we think that it is important to study long-term use, and to include both histological assessment and evaluation of endocrine function. In our immunological evaluation, CD4-positive lymphocytes were dominant in the in ammatory cell in ltration in the pancreatitis group and 2 mg group. IFN-R -positive cell in ltration was observed at sites where in ammatory cell in ltration was strong. Although the pathogenesis of AIP is not yet fully understood, involvement of Th1 has been suggested to occur during early lesion formation. In the immunogenetic background, abnormality of the innate immune system, and acquired immune system shift to Th2, and regulatory T cells are thought to be involved in the pathogenesis 18 19 . In pancreatic tissue of type 1 AIP, in ltration of regulatory T cells Tregs and IgG4-positive cells has been observed. It is thought that peripherally induced inducible co-stimulatory molecule ICOS -positive inducible memory Treg i-Treg is involved in IgG4 production, and ICOS-negative Treg is involved in brosis via TGF- 20 . In the innate immune system, IgG4 production may be induced by BAFF B-cell activating factor produced from monocytes and basophils activated via TLR toll-like receptors and NOD nucleotide-binding oligomerization domain 21 22 . In our study, in ltration of Foxp3-positive cells was suppressed in the 1 mg group, in which in ammation was suppressed. Therefore, although administration of low-dose FK506 may have a suppressive effect on regulatory T cells, we believe that veri cation with long-term administration of FK506 is necessary to achieve an inhibitory effect on brosis associated with pancreatitis. Suppression of CD11b-positive cell in ltration was also observed, and natural immunity also showed a tendency to be inhibited by FK506. However, long-term administration of FK506 is likely to provide more information about the pathogenesis of pancreatitis.
In conclusion, in animal models of AIP, low-dose FK506 can be expected to be effective against exocrine disorders, but its effect on endocrine disorders is unclear. As pancreatitis symptoms tended to worsen at the higher dose, further research is required to determine the optimal dose. Since the endocrine disorder appeared at a later stage than previously reported, it is possible that the effect on endocrine disorder might be obtained by longer-term use. Therefore, additional research is necessary.
